No End In Sight For M&A As Medtechs Adapt To The “New Normal”
The global medtech industry may be facing slow growth, rising regulatory demands and not exactly free-flowing venture capital investment. But EY finds reasons for optimism and sees opportunities for companies able to cope with the changes and move with alacrity.
You may also be interested in...
There can be no such thing as a COVID dividend, but the renewed digital push and momentum for health system change perhaps come closest.
COVID-19 has forced a rethink in how care should be delivered. Healthcomms Consulting partner Dan Jones says it is an opportunity that must not be squandered.
Certain Cumberlege Review recommendations are making their way into draft UK legislation as the government presses ahead in shaping the UK’s post-Brexit devices regulatory system.